A peer-reviewed review from researchers at Georgetown, the University of Michigan, UMass Amherst and Roswell Park has pulled together essentially everything science knows about nicotine pouches — 73 new studies published since their previous review — and the picture is more nuanced than either the alarmist or the dismissive takes suggest.

The paper, an updated scoping review in Nicotine & Tobacco Research published on 6 September 2026, covers studies through 30 September 2025. Most of the new research is American, and 12 of the 73 studies were industry-funded.

What the review found

Youth use is up, from a low base. US national surveillance shows a slow but steady increase in current pouch use among youth in 2024: 1.8% of middle and high school students in the National Youth Tobacco Survey, and 2.6% among 10th and 12th graders in Monitoring the Future.

Adult use remains low. Current use among adults was 0.4%–0.8% in 2022–2023, concentrated among ages 18–44 and people who already use tobacco.

Sales have exploded. US pouch sales more than tripled between 2021 and 2024 — far outpacing the measured prevalence numbers, which is the gap that makes regulators nervous.

Marketing is the flashpoint. The review found marketing strategies increasingly emphasize claims the authors flag as potentially youth-appealing, with online and social media as the key promotional channels.

Nicotine delivery is real. Pouches generally contain a higher proportion of freebase nicotine than other oral products, and delivery scales with strength. The review's most striking technical finding: nicotine uptake from higher-strength pouches (6mg and above) typically exceeds that from cigarettes in adult smokers — while pouches consistently score lower than cigarettes on positive subjective ratings, meaning they are less satisfying even when they deliver more nicotine.

On switching and cessation

Preliminary evidence from short-term, heterogeneous studies suggests pouch use can reduce smoking in daily smokers — but the review notes the typical outcome is dual use rather than complete cigarette cessation. That distinction matters: pouches are doing something, but the evidence does not yet show them replacing cigarettes at the population level.

Why it matters

The review's bottom line on toxicity is straightforward: pouches are considerably less toxic than cigarettes, but their long-term health impacts remain understudied. The authors conclude that more research is needed on health effects, on whether pouches work for long-term smoking cessation, and on their broader public health impact in people who never used tobacco.

For the pouch industry, this is both good and bad news. The "less toxic than cigarettes" finding supports the harm-reduction case regulators in Sweden and increasingly in Brussels are weighing. But the tripling sales, the rising youth numbers and the freebase-nicotine delivery data are exactly the figures flavour-ban and plain-packaging proposals — including the EU committee vote earlier this week — are built to address. The study every side will quote in the TPD revision debate now exists.

---

Compare nicotine pouch brands and prices at PouchFinder.

SOURCES:

• Travis N, Warner KE, Hartmann-Boyce J, Goniewicz ML, Ma C, Meza R, Levy DT. "Oral Nicotine Pouches and Public Health: Evidence from an Updated Scoping Review." Nicotine & Tobacco Research (2026). DOI: 10.1093/ntr/ntag203 — published 6 September 2026
• All figures cited from the article's abstract as retrieved from Oxford Academic